open access
Subcutaneous implantable cardioverter-defibrillator therapy in Poland: Results of the Polish S-ICD Registry
Affiliations- Department of Cardiology and Electrotherapy, Medical University of Gdansk, Gdańsk, Poland
- 3rd Department of Cardiology, School of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland
- 2nd Department of Heart Arrhythmia, National Institute of Cardiology, Warszawa, Poland
- Department of Cardiology and Internal Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland
- 1st Department of Cardiology, Medical University of Warsaw, Warszawa, Poland
- Department of Electrocardiology, John Paul II Hospital, Kraków, Poland
- Institute of Heart Diseases, Wroclaw Medical University, Wrocław, Poland
- 1st Department of Cardiology, University of Medical Sciences, Poznań, Poland
- Department of Electrocardiology, Medical University of Lodz, Łódź, Poland
- Department of Cardiology and Internal Diseases, Military Institute of Medicine — National Research Institute, Warszawa, Poland
- Chair and Department of Cardiology Medical University of Lublin, Lublin, Poland
- 1st Department of Cardiology with the Acute Coronary Syndromes Subdivision, Clinical Provincial Hospital No. 2, Rzeszów, Poland
- 1st Chair and Department of Cardiology, Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland
- Silesian Center for Heart Diseases 1st Department of Cardiology and Angiology, Zabrze, Poland
- Medical University of Silesia, Faculty of Health Sciences, Department of Dietetics, Bytom, Poland
- Department of Cardiology and Interventional Angiology, Kashubian Center for Heart and Vascular Diseases, Pomeranian Hospitals, Wejherowo, Poland
- Department of Cardiology, Center for Heart Diseases, 4th Military Hospital, Wrocław, Poland
- Medical College of Rzeszow University, Rzeszów, Poland
open access
Abstract
Background: The use of a subcutaneous implantable cardioverter-defibrillator (S-ICD) has been expanding in Poland since 2014. The Polish Registry of S-ICD Implantations was held by the Heart Rhythm Section of the Polish Cardiac Society between May 2020 and September 2022 to monitor the implementation of that therapy in Poland.
Aims: To investigate and present the state-of-the-art of S-ICD implantation in Poland.
Methods: Implanting centers reported clinical data of patients undergoing S-ICD implantations and replacements, including: age, gender, height, weight, underlying disease, history of pacemaker and defibrillator implantations, indications for S-ICD, electrocardiographical parameters, procedural techniques, and complications.
Results: 440 patients undergoing S-ICD implantation (411) or replacement (29) were reported by 16 centers. Most patients were in New York Heart Association class II (218 patients, 53%) or I (150 patients, 36.5%). Left ventricular ejection fraction was 10-80%, median (IQR) 33% (25%‒55%). Primary prevention indications were present in 273 patients (66.4%). Non-ischemic cardiomyopathy was reported in 194 patients (47.2%). The main reason for the choice of S-ICD were: young age (309, 75.2%), risk of infective complications (46, 11.2%), prior infective endocarditis (36, 8.8%), hemodialysis (23, 5.6%), and immunosuppressive therapy (7, 1.7%). Electrocardiographic screening was performed in 90% of patients. The rate of adverse events was low (1.7%). No surgical complications were observed.
Conclusions: Qualification for S-ICD in Poland was slightly different when compared to the rest of Europe. The implantation technique was mostly consistent with the current guidelines. S-ICD implantation was safe, and the complication rate was low.
Abstract
Background: The use of a subcutaneous implantable cardioverter-defibrillator (S-ICD) has been expanding in Poland since 2014. The Polish Registry of S-ICD Implantations was held by the Heart Rhythm Section of the Polish Cardiac Society between May 2020 and September 2022 to monitor the implementation of that therapy in Poland.
Aims: To investigate and present the state-of-the-art of S-ICD implantation in Poland.
Methods: Implanting centers reported clinical data of patients undergoing S-ICD implantations and replacements, including: age, gender, height, weight, underlying disease, history of pacemaker and defibrillator implantations, indications for S-ICD, electrocardiographical parameters, procedural techniques, and complications.
Results: 440 patients undergoing S-ICD implantation (411) or replacement (29) were reported by 16 centers. Most patients were in New York Heart Association class II (218 patients, 53%) or I (150 patients, 36.5%). Left ventricular ejection fraction was 10-80%, median (IQR) 33% (25%‒55%). Primary prevention indications were present in 273 patients (66.4%). Non-ischemic cardiomyopathy was reported in 194 patients (47.2%). The main reason for the choice of S-ICD were: young age (309, 75.2%), risk of infective complications (46, 11.2%), prior infective endocarditis (36, 8.8%), hemodialysis (23, 5.6%), and immunosuppressive therapy (7, 1.7%). Electrocardiographic screening was performed in 90% of patients. The rate of adverse events was low (1.7%). No surgical complications were observed.
Conclusions: Qualification for S-ICD in Poland was slightly different when compared to the rest of Europe. The implantation technique was mostly consistent with the current guidelines. S-ICD implantation was safe, and the complication rate was low.
Keywords
implantable cardioverter-defibrillator, subcutaneous implantable cardioverter-defibrillator, sudden cardiac death, ventricular arrhythmia
About this articleTitle
Subcutaneous implantable cardioverter-defibrillator therapy in Poland: Results of the Polish S-ICD Registry
Journal
Kardiologia Polska (Polish Heart Journal)
Issue
Article type
Original article
Published online
2023-02-19
Page views
70
Article views/downloads
47
DOI
10.33963/KP.a2023.0046
Pubmed
Keywords
implantable cardioverter-defibrillator
subcutaneous implantable cardioverter-defibrillator
sudden cardiac death
ventricular arrhythmia
Authors
Maciej Kempa
Szymon Budrejko
Mateusz Tajstra
Paweł Syska
Michał Lewandowski
Tomasz Fabiszak
Marcin Michalak
Adrian Stanek
Krzysztof Nowak
Przemysław Mitkowski
Krzysztof Kaczmarek
Zbigniew Orski
Marcin Janowski
Piotr Szafarz
Artur Filipecki
Adam Sokal
Marek Szołkiewicz
Dariusz Jagielski
Andrzej Przybylski
References (22)- Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2018; 72(14): 1677–1749.
- Aktaa S, Tzeis S, Gale CP, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022; 43(40): 3997–4126.
- Kaczmarek K, Kempa M, Grabowski M, et al. A subcutaneous implantable cardioverter-defibrillator - the first implantation in Poland. Kardiol Pol. 2015; 73(1): 62–771.
- Regulation of the Polish Minister of Health of January 9, 2019. Regulation on the procedure guaranteed in the field of hospital treatment [in Polish]. Available online: http://isap.sejm.gov.pl/isap.nsf/download.xsp/WDU20190000077/O/D20190077.pdf. [Access: February 4, 2023].
- Kempa M, Przybylski A, Budrejko S, et al. Multicenter Registry of Subcutaneous Cardioverter- -Defibrillator Implantations: a preliminary report. Kardiol Pol. 2021; 79(6): 697–699.
- Kempa M, Przybylski A, Budrejko S, et al. Utilization of Subcutaneous Cardioverter-Defibrillator in Poland and Europe-Comparison of the Results of Multi-Center Registries. Int J Environ Res Public Health. 2021; 18(13).
- Kempa M, Przybylski A, Budrejko S, et al. Evolution of implantation technique and indications for a subcutaneous cardioverter-defibrillator: over 7 years of experience in Poland. Kardiol Pol. 2021; 79(9): 1016–1018.
- Jędrzejczyk-Patej E, Boveda S, Kalarus Z, et al. Factors determining the choice between subcutaneous or transvenous implantable cardioverter-defibrillators in Poland in comparison with other European countries: a sub-study of the European Heart Rhythm Association prospective survey. Kardiol Pol. 2018; 76(11): 1507–1515.
- Sosnowska-Pasiarska B, Bartkowiak R, Wożakowska-Kapłon B, et al. Population of Polish patients participating in the Heart Failure Pilot Survey (ESC-HF Pilot). Kardiol Pol. 2013; 71(3): 234–240.
- Kempa M, Opielowska-Nowak B, Budrejko S, et al. A survey study of the use of a subcutaneous implantable cardioverter-defibrillator in various clinical scenarios by expert electrophysiologists in Poland. Cardiol J. 2022 [Epub ahead of print].
- Boersma LV, El-Chami M, Steinwender C, et al. Practical considerations, indications, and future perspectives for leadless and extravascular cardiac implantable electronic devices: a position paper by EHRA/HRS/LAHRS/APHRS. Europace. 2022; 24(10): 1691–1708.
- Giacomin E, Falzone PV, Dall'Aglio PB, et al. Subcutaneous implantable cardioverter defibrillator after transvenous lead extraction: safety, efficacy and outcome. J Interv Card Electrophysiol. 2022 [Epub ahead of print].
- Lambiase PD, Barr C, Theuns DA, et al. Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry. Eur Heart J. 2014; 35(25): 1657–1665.
- Boersma L, Barr C, Knops R, et al. Implant and Midterm Outcomes of the Subcutaneous Implantable Cardioverter-Defibrillator Registry: The EFFORTLESS Study. J Am Coll Cardiol. 2017; 70(7): 830–841.
- Quast AFBE, Baalman SWE, Brouwer TF, et al. A novel tool to evaluate the implant position and predict defibrillation success of the subcutaneous implantable cardioverter-defibrillator: The PRAETORIAN score. Heart Rhythm. 2019; 16(3): 403–410.
- Heist EK, Belalcazar A, Stahl W, et al. Determinants of subcutaneous implantable cardioverter-defibrillator efficacy: a computer modeling study. JACC Clin Electrophysiol. 2017; 3(4): 405–414.
- Russo V, Viani S, Migliore F, et al. Lead Abandonment and Subcutaneous Implantable Cardioverter-Defibrillator (S-ICD) Implantation in a Cohort of Patients With ICD Lead Malfunction. Front Cardiovasc Med. 2021; 8: 692943.
- Iavarone M, Rago A, Nigro G, et al. Inappropriate shocks due to air entrapment in patients with subcutaneous implantable cardioverter-defibrillator: A meta-summary of case reports. Pacing Clin Electrophysiol. 2022; 45(10): 1210–1215.
- Nishinarita R, Kishihara J, Matsuura G, et al. Early inappropriate shock in a subcutaneous cardiac defibrillator due to subcutaneous air. J Arrhythm. 2019; 35(4): 682–684.
- Gold MR, Lambiase PD, El-Chami MF, et al. Primary Results From the Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection Fraction (UNTOUCHED) Trial. Circulation. 2021; 143(1): 7–17.
- Boersma LV, El-Chami MF, Bongiorni MG, et al. Understanding Outcomes with the EMBLEM S-ICD in Primary Prevention Patients with Low EF Study (UNTOUCHED): Clinical characteristics and perioperative results. Heart Rhythm. 2019; 16(11): 1636–1644.
- Budrejko S, Kempa M, Królak T, et al. Procedural volume of cardiac electrotherapy procedures does not have to be reduced during COVID-19 pandemic - one year analysis from a tertiary Polish center. Kardiol Pol. 2021; 79(7-8): 848–850.
